Skadden Advises Endo On $1.2B Qualitest Purchase

Law360, New York (September 28, 2010, 7:31 PM EDT) -- Endo Pharmaceuticals said Tuesday it has agreed to buy privately held generic drug company Qualitest Pharmaceuticals in a $1.2 billion deal that will expand its offerings in pain management drugs.

The Chadds Ford, Pa.-based company will acquire 100 percent of Qualitest, the sixth-largest generics maker in the U.S. by prescriptions filled, for $1.2 billion in cash from private equity group Apax Partners.

It will fund the purchase with $500 million in cash from its balance sheet, drawing down an existing $300 million revolving credit facility, and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.